July was nonstop at Apex AI.
From groundbreaking steps in life-saving AI tech to major developments in Internet Capital Markets, here’s every key moment from July ↓
Apex AI's CEO Sung Kim represented Apex AI at the 2025 Medical Device Development Program briefing, outlining our accelerated path to KFDA & U.S. FDA approvals for AI-powered early GI cancer detection.
CEO Sung Kim represented Apex AI at the 2025 Medical Device Development Program briefing, driving our strategic approach to KFDA approval for our AI-powered early GI-cancer detection.
Next steps:
• Head-to-head evaluation of hospital accelerators at Ajou University Hospital (#7 in Korea) and current partner Inha University Hospital (#13) to optimize KFDA approval path.
• Leverage new Korean AI-medical-device regs & ISO alignment, speeding future U.S. FDA filing.
Clear regulatory runway ahead. AI powered early GI cancer detection is closer than ever.
We visited Davos Hospital for an on-site interview and product demo with Dr. Won Jin Ko, who’s been instrumental in building Apex AI for the past four years.
“Early-stage cancer can be missed during an endoscopy. With Apex AI’s real-time detection, we can perform a biopsy right away, which is amazing.”
— Dr. Won Jin Ko (Vice Director at Davos Hospital)
After 4 years of collaborative research, Apex AI’s early cancer detection platform is finalized and ready for KFDA/FDA approval.
Real-time detection, precise year-over-year tracking, and AI-powered diagnostics.
Early detection saves lives. $APEX makes it happen.
Major update: Apex AI’s acute kidney injury predictor is now integrated at Inha University Hospital, enabling real-time detection and timely clinical intervention.
MAJOR UPDATE AT INHA UNIVERSITY HOSPITAL
Apex AI's acute‑kidney‑injury predictor is now integrated with Inha University Hospital's next‑gen data center.
Soon, live ICU vitals and lab results will stream straight into the Apex AI engine, which detects the earliest signs of kidney stress and alerts clinicians in time to act before irreversible damage sets in.
The same platform that underpins our GI‑cancer detection system is architected to tackle various other critical conditions. Wherever real‑time clinical data lives, Apex AI can turn it into life‑saving foresight.
Stay tuned for what’s coming next.
CEO Sung Kim advanced Apex AI’s SaMD approval process with Ajou University Hospital, accelerating real-time deployment for early GI cancer detection.
SaMD Approval Countdown Has Begun
Apex AI CEO Sung Kim locked in the roadmap with Ajou University Hospital’s Medical‑Device Support Center and their leading GI team to take our GI cancer early‑detection AI through Korea’s SaMD (Software as a Medical Device) gate.
Regulatory files are in prep, validation plans are set, and every box we tick moves the platform closer to real‑time deployment in hospitals.
$APEX saves lives.
Patent officially registered: Our internal tool automating false-positive detection in medical AI training is now patented and registered, significantly cutting development time and costs.
PATENT OFFICIALLY REGISTERED
Our patent, approved last month, is now officially registered! This groundbreaking internal tool automates the detection of false positives and negatives during medical AI training, slashing development time and costs.
Verify it yourself at with patent number: 1020200003735
July set the stage for the next chapter: ICM Phase 2 is here, transforming investment access, driving real-world innovation, and empowering $APEX to save lives.
Together, we're building the future.
4,1 тыс.
0
Содержание этой страницы предоставляется третьими сторонами. OKX не является автором цитируемых статей и не имеет на них авторских прав, если не указано иное. Материалы предоставляются исключительно в информационных целях и не отражают мнения OKX. Материалы не являются инвестиционным советом и призывом к покупке или продаже цифровых активов. Раздел использует ИИ для создания обзоров и кратких содержаний предоставленных материалов. Обратите внимание, что информация, сгенерированная ИИ, может быть неточной и непоследовательной. Для получения полной информации изучите соответствующую оригинальную статью. OKX не несет ответственности за материалы, содержащиеся на сторонних сайтах. Цифровые активы, в том числе стейблкоины и NFT, подвержены высокому риску, а их стоимость может сильно колебаться. Перед торговлей и покупкой цифровых активов оцените ваше финансовое состояние и принимайте только взвешенные решения.